0000950170-23-013722.txt : 20230420
0000950170-23-013722.hdr.sgml : 20230420
20230420181719
ACCESSION NUMBER: 0000950170-23-013722
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230418
FILED AS OF DATE: 20230420
DATE AS OF CHANGE: 20230420
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Miller Andrew Craig
CENTRAL INDEX KEY: 0001777760
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38958
FILM NUMBER: 23834136
MAIL ADDRESS:
STREET 1: C/O KARUNA THERAPEUTICS, INC.
STREET 2: 33 ARCH STREET, SUITE 3110
CITY: BOSTON
STATE: MA
ZIP: 02110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karuna Therapeutics, Inc.
CENTRAL INDEX KEY: 0001771917
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270605902
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HIGH STREET
STREET 2: 26TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 857-449-2244
MAIL ADDRESS:
STREET 1: 99 HIGH STREET
STREET 2: 26TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
ownership.xml
4
X0407
4
2023-04-18
0001771917
Karuna Therapeutics, Inc.
KRTX
0001777760
Miller Andrew Craig
C/O KARUNA THERAPEUTICS, INC.
99 HIGH STREET, 26TH FLOOR
BOSTON
MA
02110
false
true
false
false
Chief Operating Officer
true
Common Stock
2023-04-18
4
M
false
30000
9.20
A
60900
D
Common Stock
2023-04-18
4
S
false
30000
200.16
D
30900
D
Common Stock
2023-04-20
4
M
false
8500
9.20
A
39400
D
Common Stock
2023-04-20
4
S
false
15000
200.13
D
24400
D
Option (right to buy)
9.20
2023-04-18
4
M
false
30000
0
D
2029-03-20
Common Stock
30000
240492
D
Option (right to buy)
9.20
2023-04-20
4
M
false
8500
0
D
2029-03-20
Common Stock
8500
231992
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2022.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.04 to $200.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
This option vested and became exercisable in thirty equal monthly installments beginning on April 21, 2019.
/s/ Troy Ignelzi, Attorney-in-Fact
2023-04-20